NIM811, a nonimmunosuppressive cyclosporine analogue, suppresses collagen production and enhances collagenase activity in hepatic stellate cells

Liver International

Volumn 27, Issue 9, 2007, Pages 1273-1281

  Kohjima, Motoyuki ^a   Enjoji, Munechika ^a   Higuchi, Nobito ^a   Kotoh, Kazuhiro ^a   Kato, Masaki ^a   Takayanagi, Ryoiichi ^a   Nakamuta, Makoto ^a,b  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

Author keywords

Cyclosporine analogue; Hepatic fibrosis; Hepatic stellate cell; NIM811; TGF

Indexed keywords

ANTIFIBROTIC AGENT; COLLAGEN; COLLAGENASE; CYCLOSPORIN A; CYCLOSPORIN DERIVATIVE; INTERSTITIAL COLLAGENASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; NIM 811; NIM 881; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD7 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL GROWTH; CELL PROLIFERATION; COLLAGEN SYNTHESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SCREENING; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; LIVER CELL; LIVER CELL CULTURE; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; STELLATE CELL; TRANSCRIPTION REGULATION;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; COLLAGEN TYPE I; COLLAGENASES; CYCLOSPORINE; HEPATOCYTES; LIVER; MALE; MATRIX METALLOPROTEINASE 1; PHOSPHORYLATION; RATS; RATS, WISTAR; SMAD2 PROTEIN; SMAD3 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 35148889830     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2007.01560.x     Document Type: Article

References (45)

1. Prieto M, Berenguer M, Rayón M, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodes. Hepatology 1998; 29: 250-6.
2. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: Increase in recent years. J Hepatol 2000; 32: 673-4.
3. Berenguer M, Prieto M, Juan FS, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 202-10.
4. Berenguer M. Natural history of recurrent hepatitis C. Liver Transplant 2002; 8: S14-8.
5. Berenguer M, Crippin J, Gish R, et al. A model to predict severe HCV-related disease following liver transplantation. Hepatology 2003; 38: 34-41.
6. Pollard S. Calcineurin inhibition and disease recurrence in the hepatitis C virus-positive liver transplant recipient. Liver Int 2004; 24: 402-6.
7. Friedman SL. Hepatic stellate cells. Prog Liver Dis 1996; 14: 101-30.
8. Friedman SL. The cellular basis of hepatic fibrosis: Mechanisms and treatment strategies. N Engl J Med 1993; 328: 1828-35.
9. Nakamuta M, Kohjima M, Fukushima M, et al. Cyclosporine suppresses cell growth and collagen production in hepatic stellate cells. Transplant Proc 2005; 37: 4598-602.
10. Clipstone NA, Crabtree GR. Identification of calcineurin as a key signaling enzyme in T-lymphocyte activation. Nature 1992; 357: 695-7.
11. Shaw KT, Ho AM, Raghavan A, et al. Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells. Proc Natl Acad Sci USA 1995; 92: 11205-9.
12. Macian F, Lopez-Rodriguez C, Rao A. Partners in transcription: NFAT and AP-1. Oncogene 2001; 20: 2476-89.
13. Waldmeier PC, Feldtrauer JJ, Qian T, Lemasters JJ. Inhibition of the mitochondrial permeability transition by the nonimmunosuppressive cyclosporin derivative NIM811. Mol Pharmacol 2002; 62: 22-9.
14. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38: 1282-8.
15. Kato M, Iwamoto H, Higashi N, et al. Role of Rho small GTP binding protein in the regulation of actin cytoskeleton in hepatic stellate cells. J Hepatol 1999; 31: 91-9.
16. Shibata N, Watanabe T, Okitsu T, et al. Establishment of an immortalized human hepatic stellate cell line to develop antifibrotic therapies. Cell Transplant 2003; 12: 499-507.
17. Iwamoto H, Nakamuta M, Tada S, Sugimoto R, Enjoji M, Nawata H. A p160ROCK-specific inhibitor, Y-27632, attenuates rat hepatic stellate cell growth. J Hepatol 2000; 32: 762-70.
18. Fukushima M, Nakamuta M, Kohjima M, et al. Fasudil hydrochloride hydrate, a Rho-kinase (ROCK) inhibitor, suppresses collagen production and enhances collagenase activity in hepatic stellate cells. Liver Int 2005; 25: 829-38.
19. Nakamuta M, Kohjima M, Morizono S, et al. Evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int J Mol Med 2005; 16: 631-5.
20. Shegogue D, Trojanowska M. Mammalian target of rapamycin positively regulates collagen type one production via a phosphatidylinositol 3-kinase-independent pathway. J Biol Chem 2004; 279: 23166-75.
21. Reuben PM, Brogley MA, Sun Y, Cheung HS. Molecular mechanism of the induction of metalloproteinases 1 and 3 in human fibroblasts by basic calcium phosphate crystals. J Biol Chem 2002; 277: 15190-8.
22. Tachibana K, Shimizu T, Tonami K, Takeda K. Staurosporine enhances the expression of tissue inhibitor of metalloproteinase-1 in human prostate cancer cells. Biochem Biophys Res Commun 2002; 295: 489-94.
23. Quan T, He T, Voorhees JJ, Fisher GJ. Ultraviolet irradiation induces Smad7 via induction of transcription factor AP-1 in human skin fibroblasts. J Biol Chem 2005; 80: 8079-85.
24. Woszczyk D, Gola J, Jurzak M, Mazurek U, Mykala-Ciesla J, Wilczok T. Expression of TGF beta1 genes and their receptor types I, II, and III in low- and high-grade malignancy non-Hodgkin's lymphomas. Med Sci Monit 2004; 10: 33-7.
25. Higashi N, Kohjima M, Fukushima M, et al. Epigallocatechin-3-gallate, a green-tea polyphenol, suppresses Rho signaling in TWNT-4 human hepatic stellate cells. J Lab Clin Med 2005; 145: 316-22.
26. Uchimura K, Nakamuta M, Enjoji M, et al. Activation of retinoic X receptor and peroxisome proliferatior-activated receptor-γ inhibits nitric oxide and tumor necrosis factor-α production in rat Kupffer cells. Hepatology 2001; 33: 91-9.
27. Friedman SL, Yamasaki G, Wong L. Modulation of transforming growth factor beta receptors of rat lipocytes during the hepatic wound healing response. Enhanced binding and reduced gene expression accompany cellular activation in culture and in vivo. J Biol Chem 1994; 269: 10551-8.
28. Hayashi H, Abdollah S, Qiu Y, et al. The MAD-related protein Smad7 associates with the TGFβ receptor and functions as an antagonist of TGFβ signaling. Cell 1997; 89: 1165-73.
29. Benyon RC, Iredale JP, Goddard S, Winwood PJ, Arthur MJP. Expression of tissue inhibitor of metalloproteinases-1 and -2 is increased in fibrotic human liver. Gastroenterology 1996; 110: 821-31.
30. Iredale JP, Benyon RC, Arthur MJP, et al. Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis. Hepatology 1996; 24: 176-84.
31. Iredale JP, Murphy G, Hembry RM, Friedman SL, Arthur MJP. Human hepatic lipocytes synthesized tissue inhibitor of metalloproteinase-1 (TIMP-1): implications for regulation of matrix degradation in liver. J Clin Invest 1992; 90: 282-7.
32. Murphy FR, Issa R, Zhou X, et al. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition. J Biol Chem 2002; 277: 11069-76.
33. Marr F, Arrighi MC, Fazi M, et al. Extracellular signal-regulated kinase activation differentially regulates platelet-derived growth factor's actions in hepatic stellate cells, and is induced by in vivo liver injury in the rat. Hepatology 1999; 30: 951-8.
34. Mastuda S, Shibasaka F, Takehara K, Mori H, Nishida E, Koyasu S. Two distinct action mechanisms of immunophilin-ligand complex for the blockade of T-cell activation. EMBO Rep 2000; 1: 428-34.
35. Wrana JL, Attisano L. The Smad pathway. Cytokine Growth Factor Rev 2000; 11: 5-13.
36. Inagaki Y, Mamura M, Kanamaru Y, et al. Constitutive phosphorylation and nuclear localization of Smad3 are correlated with increased collagen gene transcription in activated hepatic stellate cells. J Cell Physiol 2001; 187: 117-23.
37. Nakao A, Afrakhte M, Moren A, et al. Identification of Smad7, a TGF-β-inducible antagonist of TGF-β signaling. Nature 1997; 389: 631-5.
38. Wang T, Donahoe PK, Zervos AS. Specific interaction of type I receptors of TGF-β family with the immunophilin FKBP-12. Science 1994; 265: 674-6.
39. Tsukazaki T, Chiang TA, Davison AF, Attisano L, Wrana JL. SARA, a FYVE domain protein that recruits Smad2 to the TGFβ receptor. Cell 1998; 95: 779-91.
40. Waldmeier PC, Zimmermann K, Qian T, Tintelnot-Blomley M, Lemasters JJ. Cycophilin D as a drug target. Curr Med Chem 2003; 10: 1485-506.
41. Duina AA, Chang HC, Marsh JA, Lindquist S, Gaver RF. A cyclophilin function in Hsp-90-dependent signal trasduction. Science 1996; 274: 1713-5.
42. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohono K. Cyclosporine A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38: 1282-8.
43. Watashi K, Ishii N, Hijikata M, et al. Cyclophilin B is a fuctional regulator of Hepatitis C virus RNA polymerase. Mol Cell 2005; 19: 111-22.
44. Kon K, Kim JS, Jaeschke H, Lemasters JJ. Mitochondrial permeability transition in acetaminophen-induced necrosis and apoptosis of culture mouse hepatocytes. Hepatology 2004; 40: 1170-9.
45. Rosenwirth B, Billich A, Datema R, et al. Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM811, a nonimmunosuppressive cyclosporine analog. Antimicrob Agents Chemother 1994; 38: 1763-72.